ChiCTR2600123482 版本V1.0 版本创建时间2026/04/27 14:26:35 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600123482 

最近更新日期:

Date of Last Refreshed on:

2026-04-27 14:26:00 

注册时间:

Date of Registration:

2026-04-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

眉山市东坡区3~12岁儿童矮小症流行病学调查及影响因素分析

Public title:

Epidemiological Survey and Influencing Factor Analysis of Short Stature in Children Aged 3-12 Years in Meishan Dongpo District

注册题目简写:

English Acronym:

ESIF-SS-3-12Y-MS

研究课题的正式科学名称:

眉山市东坡区3~12岁儿童矮小症流行病学调查及影响因素分析

Scientific title:

3~12Epidemiological Survey and Influencing Factor Analysis of Short Stature in Children Aged 3-12 Years in Dongpo District, Meishan City

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张卉婷 

研究负责人:

张卉婷 

Applicant:

Zhang Huiting 

Study leader:

Zhang Huiting 

申请注册联系人电话:

Applicant telephone:

+86 28 3850 9261

研究负责人电话:

Study leader's
telephone:

+86 28 3850 9261

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zht850506@163.com

研究负责人电子邮件:

Study leader's E-mail:

244930075@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

眉山市东坡区东坡大道南四段288号

研究负责人通讯地址:

眉山市东坡区东坡大道南四段288号

Applicant address:

No.288, South Section 4, Dongpo Avenue, Dongpo District, Meishan City

Study leader's address:

No.288, South Section 4, Dongpo Avenue, Dongpo District, Meishan City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

眉山市人民医院

Applicant's institution:

Meishan People's Hospital, Sichuan Province, P.R. China

研究负责人所在单位:

眉山市人民医院

Affiliation of the Leader:

Meishan City Peoples Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

MY-IBR20260015

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

眉山市人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Meishan City People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-03-06 00:00:00

伦理委员会联系人:

王秋婷

Contact Name of the ethic committee:

Wang Qiuting

伦理委员会联系地址:

眉山市东坡区东坡大道南四段288号

Contact Address of the ethic committee:

No.288, South Section 4, Dongpo Avenue, Dongpo District, Meishan City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 38235337

伦理委员会联系人邮箱:

Contact email of the ethic committee:

630191908@qq.com

研究实施负责(组长)单位:

眉山市人民医院

Primary sponsor:

Meishan City Peoples Hospital

研究实施负责(组长)单位地址:

眉山市东坡区东坡大道南四段288号

Primary sponsor's address:

No.288, South Section 4, Dongpo Avenue, Dongpo District, Meishan City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

眉山市人民医院

具体地址:

眉山市东坡区东坡大道南四段288号

Institution
hospital:

Meishan City Peoples Hospital

Address:

No.288, South Section 4, Dongpo Avenue, Dongpo District, Meishan City

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-funded by the research team, independent self-financed project

研究疾病:

儿童矮小症  

Target disease:

Growth Retardation

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

本研究对眉山地区3~12岁儿童进行流行病学调查,旨在为眉山地区儿童矮小症的早期预防和干预提供本地化数据和理论支持。  

Objectives of Study:

This study conducted an epidemiological investigation on children aged 3 to 12 in Meishan area, aiming to provide localized data and theoretical support for early prevention and intervention of dwarfism in children in Meishan area.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄3~12岁;
2.眉山市东坡区地区常住人口并且在我院儿保建档儿童中9000-10000例;
3.视听功能以及言语功能正常;

Inclusion criteria

1. 3~12Children aged 3 to 12 years old; 2. Permanent residents in Dongpo District, Meishan City, with health records established in the Department of Child Health of our hospital; 3. Normal audiovisual and verbal functions, able to cooperate with physical measurement;

排除标准:

1.患已知的染色体异常、严重先天畸形等;
2.过去一年内曾长期(连续超过3个月)或大剂量使用过可能影响生长的药物;
3.存在严重认知或行为障碍,不能够配合完成基本体格测量、问卷调查等;

Exclusion criteria:

1. Known chromosomal abnormalities, severe congenital malformations, chronic systemic diseases and other diseases affecting growth and development; 2.?Continuous use for >=3 months or high-dose use of drugs that may affect growth and development (such as glucocorticoids, immunosuppressants, etc.) in the past 12 months; 3. Severe cognitive impairment, mental behavioral abnormalities, unable to cooperate with physical measurement and data collection;

研究实施时间:

Study execute time:

From 2026-05-01 00:00:00 To 2027-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-01 00:00:00 To 2027-05-01 00:00:00

干预措施:

Interventions:

组别:

眉山市东坡区3~12岁儿童队列(矮小症组、正常身高对照组)

样本量:

10000

Group:

Children aged 3-12 years in Dongpo District, Meishan City (Short Stature Group, Normal Height Control Group)

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

眉山市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Meishan City Peoples Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

睡眠时长

指标类型:

主要指标

Outcome:

sleep duration

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

性别

指标类型:

主要指标

Outcome:

gender

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

年龄

指标类型:

主要指标

Outcome:

age

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

出生胎龄

指标类型:

主要指标

Outcome:

gestational age

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

出生体重

指标类型:

主要指标

Outcome:

birth weight

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

慢性病史

指标类型:

主要指标

Outcome:

chronic disease history

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

父母身高

指标类型:

主要指标

Outcome:

parental height

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

喂养方式

指标类型:

主要指标

Outcome:

feeding pattern

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

挑食偏食

指标类型:

主要指标

Outcome:

dietary habits

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

钙质摄入

指标类型:

主要指标

Outcome:

calcium intake

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体育锻炼时间

指标类型:

主要指标

Outcome:

physical exercise time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 3 years
最大 Max age 12 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本研究为回顾性临床观察性研究,涉及受试者隐私保护,原始数据不予公开共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

This is a retrospective observational clinical study involving the protection of subjects' privacy, and the original data will not be publicly shared.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用标准化数据采集与管理流程:1. 设计统一的电子病例报告表(CRF),规范收集研究相关信息;2. 依托医院电子病历系统及科研数据管理平台(EDC)完成数据录入、存储;3. 实行双人双录入、逻辑核查,确保数据准确完整;4. 严格去标识化处理,保护受试者隐私,遵守相关法律法规

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This study adopts a standardized data collection and management process: 1. Design a unified electronic Case Report Form (CRF) to standardize the collection of research-related information; 2. Rely on the hospital's electronic medical record system and scientific research data management platform (EDC) to complete data entry and storage; 3. Implement double data entry and logical verification to ensure the accuracy and integrity of the data; 4. Strictly de-identify the data to protect the privacy of subjects and comply with relevant laws and regulations

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-04-27 14:26:00